ATE472323T1 - Behandlung von statin-nebenwirkungen mit uridinderivaten - Google Patents

Behandlung von statin-nebenwirkungen mit uridinderivaten

Info

Publication number: ATE472323T1
Authority: AT; Austria
Prior art keywords: treatment; derivatives; side effects; urideine; uridine
Prior art date: 2001-12-13

Application number

AT02780979T

Other languages

English (en)

Inventor

Anthony Linnane

Original Assignee

Magral Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-13

Filing date

2002-12-13

Publication date

2010-07-15

2002-12-13 Application filed by Magral Ltd filed Critical Magral Ltd

2010-07-15 Application granted granted Critical

2010-07-15 Publication of ATE472323T1 publication Critical patent/ATE472323T1/de

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 6
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 3
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 3
229940045145 uridine Drugs 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
206010049565 Muscle fatigue Diseases 0.000 abstract 1
208000000112 Myalgia Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000013465 muscle pain Diseases 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

AT02780979T 2001-12-13 2002-12-13 Behandlung von statin-nebenwirkungen mit uridinderivaten ATE472323T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPR9511A AUPR951101A0 (en)	2001-12-13	2001-12-13	Method of treatment
PCT/AU2002/001685 WO2003049730A1 (en)	2001-12-13	2002-12-13	Treatment of statin side effects using uridine derivatives

Publications (1)

Publication Number	Publication Date
ATE472323T1 true ATE472323T1 (de)	2010-07-15

Family

ID=3833127

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02780979T ATE472323T1 (de)	2001-12-13	2002-12-13	Behandlung von statin-nebenwirkungen mit uridinderivaten

Country Status (10)

Country	Link
US (2)	US20050153993A1 (de)
EP (1)	EP1465616B1 (de)
JP (1)	JP4781629B2 (de)
AT (1)	ATE472323T1 (de)
AU (2)	AUPR951101A0 (de)
CA (1)	CA2469612C (de)
DE (1)	DE60236894D1 (de)
ES (1)	ES2349686T3 (de)
NZ (1)	NZ533382A (de)
WO (1)	WO2003049730A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101360421B (zh) *	2005-11-18	2014-06-18	康乃尔研究基金会有限公司	烟酰核苷组合物及其使用方法
JP5426918B2 (ja) *	2009-04-20	2014-02-26	株式会社伊藤園	ウリジンを含有する抗疲労剤又は体力向上剤
TR2022013331A2 (tr) *	2022-08-24	2022-09-21	Bursa Uludag Ueniversitesi	Üridinin Akut Ağrıdaki Doz Bağımlı Analjezik Etkisi

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2462312A1 (de) *	1974-03-04	1976-10-14	Nadrol Chemie Pharma Keizer Kg	Arzneimittel zur behandlung von migraene-erkrankungen
FR2406959A1 (fr) *	1977-10-27	1979-05-25	Agronomique Inst Nat Rech	Additif alimentaire pour aliments contenant de l'uree
SU988814A1 (ru) *	1979-11-20	1983-01-15	Филиал Всесоюзного научно-исследовательского химико-фармацевтического института им.Серго Орджоникидзе	Соли оротовой кислоты и @ -аминокислот, предупреждающие развитие утомлени при физических нагрузках
JPS6236322A (ja) *	1985-08-08	1987-02-17	Teijin Ltd	５−フルオロ−２’−デオキシウリジン誘導体を有効成分とする抗ウイルス剤
JPS6330422A (ja) *	1986-07-24	1988-02-09	Fuji Kagaku Kogyo Kk	抗悪性腫瘍効果増強剤
CA1321994C (en) *	1987-10-28	1993-09-07	Reid Von Borstel	Acylated uridine and cytidine and uses thereof
IT1219667B (it) *	1988-06-21	1990-05-24	Polifarma Spa	Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
DE69001146T2 (de) *	1989-01-18	1993-10-07	Merck & Co Inc	Koenzym Q10 mit HMG-COA-Reduktase-Inhibitoren.
US4933165A (en) *	1989-01-18	1990-06-12	Merck & Co., Inc.	Coenzyme Q10 with HMG-CoA reductase inhibitors
US5316765A (en) *	1989-09-07	1994-05-31	Karl Folkers Foundation For Biomedical And Clinical Research	Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
ZA918336B (en) *	1990-10-19	1992-06-24	Boehringer Mannheim Italia	Udpg as a rescue agent in cancer therapy after the administration of antipyrimidine or related anti-tumor agents with or without bau
WO1993013779A2 (en) *	1991-12-16	1993-07-22	Boehringer Mannheim Italia S.P.A.	Use of udpg as cancer therapy rescue agent
BE1005939A6 (fr) *	1992-05-14	1994-03-15	Pirmez Thierry Dr	Utilisation des sels de l'acide orotique comme tranporteurs preferentiels d'oligo-elements.
US6472378B2 (en) *	1998-08-31	2002-10-29	Pro-Neuron, Inc.	Compositions and methods for treatment of mitochondrial diseases
US6245800B1 (en) *	1999-06-08	2001-06-12	Sigma-Tau	Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
AUPR177300A0 (en) *	2000-11-29	2000-12-21	Centre For Molecular Biology And Medicine	Therapeutic methods

2001
- 2001-12-13 AU AUPR9511A patent/AUPR951101A0/en not_active Abandoned
2002
- 2002-12-13 US US10/499,078 patent/US20050153993A1/en not_active Abandoned
- 2002-12-13 ES ES02780979T patent/ES2349686T3/es not_active Expired - Lifetime
- 2002-12-13 AT AT02780979T patent/ATE472323T1/de not_active IP Right Cessation
- 2002-12-13 WO PCT/AU2002/001685 patent/WO2003049730A1/en not_active Ceased
- 2002-12-13 CA CA2469612A patent/CA2469612C/en not_active Expired - Fee Related
- 2002-12-13 NZ NZ533382A patent/NZ533382A/en not_active IP Right Cessation
- 2002-12-13 AU AU2002349186A patent/AU2002349186B2/en not_active Ceased
- 2002-12-13 DE DE60236894T patent/DE60236894D1/de not_active Expired - Lifetime
- 2002-12-13 JP JP2003550779A patent/JP4781629B2/ja not_active Expired - Fee Related
- 2002-12-13 EP EP02780979A patent/EP1465616B1/de not_active Expired - Lifetime
2010
- 2010-01-22 US US12/692,045 patent/US8293755B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2002349186B2 (en)	2008-01-17
US8293755B2 (en)	2012-10-23
EP1465616A1 (de)	2004-10-13
CA2469612C (en)	2011-11-15
ES2349686T3 (es)	2011-01-10
EP1465616B1 (de)	2010-06-30
WO2003049730A1 (en)	2003-06-19
EP1465616A4 (de)	2005-04-06
DE60236894D1 (de)	2010-08-12
AUPR951101A0 (en)	2002-01-24
CA2469612A1 (en)	2003-06-19
NZ533382A (en)	2007-03-30
US20050153993A1 (en)	2005-07-14
US20100184717A1 (en)	2010-07-22
JP2005516912A (ja)	2005-06-09
JP4781629B2 (ja)	2011-09-28
AU2002349186A1 (en)	2003-06-23

Legal Events

Date	Code	Title	Description
2010-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE369845T1 (de)	2007-09-15	Behandlung der nebenwirkungen von statinen
DE60327999D1 (de)	2009-07-30	Azolylaminoazine als inhibitoren von proteinkinasen
MXPA05005223A (es)	2010-09-07	Diaminotriazoles utiles como inhibidores de proteinas cinasas.
BR0309343A (pt)	2005-02-15	Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
AU2003218215A1 (en)	2003-09-29	Azolylaminoazines as inhibitors of protein kinases
EA200500169A1 (ru)	2005-06-30	Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
ATE451376T1 (de)	2009-12-15	Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE466580T1 (de)	2010-05-15	Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de)	2007-07-15	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BR0316458A (pt)	2005-10-11	Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
MXPA03008635A (es)	2004-02-23	Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
BG108180A (en)	2004-09-30	Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EA200501310A1 (ru)	2006-06-30	Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
EA200700407A1 (ru)	2007-08-31	Производные хиназолина и их использования при лечении тромбоцитемии
NO20052699L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
MXPA06007007A (es)	2007-06-08	Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE472323T1 (de)	2010-07-15	Behandlung von statin-nebenwirkungen mit uridinderivaten
CY1110156T1 (el)	2015-01-14	Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DE602004024871D1 (de)	2010-02-11	Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
EA200600989A1 (ru)	2006-10-27	Применение габоксадола для лечения бессонницы
SG146685A1 (en)	2008-10-30	Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
DE60334289D1 (de)	2010-11-04	Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE350034T1 (de)	2007-01-15	Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60108775T8 (de)	2006-08-24	Methode zur behandlung von schlaganfall
MX2007006069A (es)	2007-07-11	Metodos para utilizar inhibidores de la fosfodiesterasa tipo v y para el tratamiento de insuficiencia cardiaca congestiva.